Verastem: hasil topline Fase 3 RAMP 301 diperkirakan pada pertengahan 2027

Presentasi korporat Maret 2026 menyatakan bahwa uji coba konfirmatori RAMP 301 Phase 3 avutometinib + defactinib versus terapi pilihan investigator pada LGSOC rekuren akan melaporkan data topline pada pertengahan 2027. Pembacaan ini dimaksudkan untuk mengonfirmasi hasil RAMP 201 dan berpotensi memperluas indikasi yang disetujui untuk AVMAPKI FAKZYNJA CO-PACK tanpa memandang status mutasi KRAS.

Fakta utama

Diajukan: 4 Mar 2026, 21.15
Peristiwa: Hasil topline
Arah: Netral
Perusahaan: VSTMVerastem
Aset: avutometinib
Sumber: SEC 8-K
Keyakinan: Bersumber

Kutipan sumber

EX-99.1 2 tm267866d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers C O R P O R A T E P R E S E N T A T I O N M A R C H 2 0 2 6 2 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements about, among other things, Verastem Oncology’s (the “Company”) programs and product candidates, strategy, future plans and prospects, including statements related to the approval and commercialization of AVMAPKIFAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) as a treatment for adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant-type (mt) recurrent Low-Grade Serous Ovarian Cancer (LGSOC), the expected outcome and benefits of collaborations, including with GenFleet Therapeutics (Shanghai), Inc

SEC 8-K